---
layout: default
title: Diclofenac
parent: 僅模型預測 (L5)
nav_order: 72
evidence_level: L5
indication_count: 10
---

# Diclofenac
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Diclofenac: Evidence Pack Incomplete — Repurposing Prediction Unavailable

## One-Sentence Summary

Diclofenac (DrugBank ID: DB00586) is a well-known non-steroidal anti-inflammatory drug (NSAID) widely used for pain and inflammation management globally.
However, the current Evidence Pack contains **no TxGNN-predicted new indications**, and key data fields including mechanism of action, original indication records, and safety warnings are absent.
As a result, **a formal repurposing analysis cannot be performed at this stage.**

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No data in Evidence Pack |
| Predicted New Indication | None — TxGNN prediction not available |
| TxGNN Prediction Score | Not applicable |
| Evidence Level | Not applicable (no prediction generated) |
| Taiwan Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why the Prediction Is Not Available

The `predicted_indications` field in this Evidence Pack is empty. This typically occurs when:

1. The TxGNN pipeline was not executed or did not return output for this drug candidate.
2. The drug was filtered out prior to the scoring step due to missing graph embedding or missing DrugBank node linkage.
3. A pipeline error occurred upstream of the prediction stage.

Without a predicted indication, the core sections of a repurposing evaluation report — mechanism-to-indication mapping, clinical trial alignment, and literature support — cannot be generated. The report cannot proceed past this point without a valid TxGNN output.

---

## Taiwan Market Information

Diclofenac has **no registered product licenses in Taiwan** according to this Evidence Pack (TFDA query returned 0 results on 2026-03-29). This is inconsistent with the global status of diclofenac, which is marketed in many countries under numerous brand names. The query result should be verified — it is possible the TFDA query used "DICLOFENAC" as the exact search string and missed records listed under Chinese INN transliterations or brand names.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This Evidence Pack is critically incomplete — there are no TxGNN-predicted indications, no original indication records, no mechanism of action data, and no safety data. No repurposing evaluation can be conducted without at minimum a predicted indication and supporting evidence.

**To proceed, the following is needed:**

- **Re-run TxGNN pipeline** for Diclofenac (DB00586) and confirm that a predicted indication output is generated
- **Retrieve MOA data** from DrugBank API (DB00586 — known COX-1/COX-2 inhibitor; should be readily available)
- **Re-query TFDA** using Chinese INN or common brand names (e.g., 待克菲納) to check for registered products
- **Retrieve safety data** from TFDA package insert (query log shows `tfda_package_insert` result_status = "success" with result_count = 1 — this data was retrieved but not parsed into the Evidence Pack)
- Once the above are resolved, re-generate Evidence Pack v5 and resubmit for evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

